05/17/2026
Meet the 96-channel electronic pipette that helped HHMI Investigator Paul Bieniasz & colleagues at The Rockefeller University run 7,000+ parallel experiments that uncovered more than 100 bNAb escape mutations across 15 viral strains. What’s it all mean? Broadly neutralizing antibodies (bNAbs) are a promising HIV treatment, but the virus is highly skilled at escaping them. Bieniasz & team used a new method to build the most comprehensive view yet of how HIV-1 builds resistance. “Knowing how different strains of the virus respond to leading bNAb therapies will greatly improve our ability to anticipate whether a particular therapy will be effective for individual patients,” says Bieniasz. bit.ly/3RCCi08
📷: Lori Chertoff
Study shows the most comprehensive view to date of how some viral strains develop drug resistance.